The United States Food and Drug Administration (USFDA) has completed an unannounced inspection at Caplin Point Laboratories’ Subsidiary, Caplin Steriles’ injectable and ophthalmic manufacturing facility located at Gummidipoondi in the Indian state of Tamil Nadu.
The inspection was conducted between August 5, 2024 and August 9, 2024 and concluded with zero observations. This outcome underscores the company’s strong commitment to maintaining the highest standards of integrity, quality, safety, and regulatory compliance in its operations.
Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.
